CD22 modulation alleviates amyloid β-induced neuroinflammation

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Neuroinflammation is a key factor in neurodegenerative diseases like Alzheimer's (AD).
• Soluble CD22 (sCD22) levels are elevated in AD patients, suggesting a role in the disease.
• The precise function of CD22 in neuroinflammation and its therapeutic potential remain unclear.

Purpose of the Study:

• To investigate the role of sCD22 in promoting neuroinflammation.
• To elucidate the mechanisms by which sCD22 activates microglia.
• To evaluate the therapeutic efficacy of targeting CD22 in AD models.

Main Methods:

• In vivo and in vitro studies using cell cultures and transgenic mouse models.
• Analysis of microglia activation pathways (p38, ERK1/2, NFκB).
• Assessment of cytokine secretion (TNFα, IL-6, IL-1β, IL-12, IL-23) and behavioral tests.

Main Results:

• sCD22 activates microglia via p38 and ERK1/2 pathways, leading to pro-inflammatory cytokine release.
• Suciraslimab, an anti-CD22 antibody, improved working memory and reduced neuroinflammation in vivo.
• Suciraslimab inhibited amyloid-beta (Aβ)-induced inflammatory signaling and enhanced Aβ-CD22 complex internalization by microglia.

Conclusions:

• sCD22 is a significant driver of neuroinflammation in AD.
• Targeting CD22 offers a dual therapeutic strategy: reducing neuroinflammation and promoting Aβ clearance.
• Suciraslimab demonstrates promising therapeutic potential for Alzheimer's disease.